益气通窍汤对急性脑梗死患者血清PPAR-γ水平的影响

Effect of Yiqi Tongqiao Decoction on Serum PPAR-γ Level of Patients with Acute Cerebral Infarction

摘要:

目的: 观察益气通窍汤治疗急性脑梗死(ACI)的临床疗效及其对血清过氧化物酶体增殖物激活受体亚型-γ(PPAR-γ)水平的影响. 方法: 将70例ACI患者采取随机法分为两组,两组均予常规治疗,治疗组给予益气通窍汤治疗,疗程为4周,观察两组治疗前后CSS评分、临床症状积分和血清PPAR-γ水平的变化.另选取同期健康体检者30例为对照组. 结果: ①治疗组、观察组各有30例完成研究.治疗组临床疗效为86.7%,高于观察组73.3%;②ACI患者血清PPAR-γ水平明显高于对照组(P<0.01);③治疗后两组临床症状积分、CSS评分和血清PPAR-γ水平均明显降低(P<0.01),且治疗组改善程度优于观察组(P<0.01);④治疗后治疗组空腹血糖(FBG),甘油三脂 (TG),总胆固醇(TC)明显下降(P<0.01),而观察组变化不显著. 结论: 在常规治疗的基础上给予益气通窍汤治疗急性脑梗死具有较显著的疗效,可明显地改善患者的临床症状、神经功能缺损和预后,动态监测ACI患者血清PPAR-γ水平,有利于评估急性脑梗死的治疗效果和病情进展.

Abstract:

Objective: To observe the clinical efficacy of Yiqi Tongqiao decoction in the treatment of acute cerebral infarction (ACI), and determine its effect on serum peroxisome proliferator activated receptor gamma (PPAR-γ) level. Method: Seventy ACI patients were randomly divided into treatment group and observation group. Patients in two groups were given conventional treatment, and patients in the treatment group added Yiqi Tongqiao decoction. The patients in both groups received a 4-week period of treatment. Changes of China stroke scale (CSS) score, clinical symptom score and serum PPAR-γ level were observed before and after treatment. Result: ①Thirty patients in both groups completed the study. Clinical efficacy of the treatment group was 86.7%, which was higher than 73.3% of the observation group. ②Serum PPAR-γ in patients with ACI was obviously higher than that of the control group (P<0.01).③After treatment, clinical symptom score, CSS score and serum PPAR-γ level of two groups were significantly decreased (P<0.01), and the results in treatment group were better than those in the observation group (P<0.01). ④After treatment fasting plasma glucose(FBG),triglycerides (TG), total cholesterol (TC) of the treatment group decreased significantly (P<0.01),while the observation group had no significant change. Conclusion: Using conventional therapy plus Yiqi Tongqiao decoction have remarkable curative effect in treating ACI. Dynamic monitoring serum PPAR-γ level is conducive to assess the effect and progression in treating ACI.